MDMA on track for 2023 approval as PTSD therapy, says develo...

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the org

MAPS 2018 EMEA Annual Meeting

Cementing the Value of Medical Affairs

A number of trends including tougher regulatory controls, increased transparency expectations, an increasingly vocal patient and greater requirements for post-marketing evidence have driven the gro

FDA names MDMA a 'breakthrough' for post-traumatic stress

US non-profit organisation to begin late-stage trials this year

Medical Affairs – the heart of a data-driven, patient-centri...

Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in recent years, and how the new Medical Affairs Professional Society (MAPS) wi